Towards the next generation of anti-TNF drugs

Clinical Immunology

Volumn 141, Issue 3, 2011, Pages 231-235

  Sfikakis, Petros P ^a,b   Tsokos, George C ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ATSTTRIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; PROGRANULIN; RECOMBINANT PROGRANULIN; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTHRITIS; CHRONIC ARTHRITIS; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; ENTERITIS; IMMUNOMODULATION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LIGAND BINDING; MULTIPLE SCLEROSIS; NONHUMAN; NOTE; OSTEOCLAST; PANNUS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UVEITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MULTIPLE SCLEROSIS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTORS; UVEITIS;

EID: 81355160312     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.09.005     Document Type: Note

References (27)

1. Apostolaki M., Armaka M., Victoratos P., Kollias G. Cellular mechanisms of TNF function in models of inflammation and autoimmunity. Curr. Dir. Autoimmun. 2010, 11:1-26.
2. Sfikakis P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr. Dir. Autoimmun. 2010, 11:180-210.
3. Hehlgans T., Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115:1-20.
4. Deng G.M., Zheng L., Chan F.K., Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat. Med. 2005, 11:1066-1072.
5. Tang W., Lu Y., Tian Q.Y., Zhang Y., Guo F.J., Liu G.Y., Syed N.M., Lai Y., Lin E.A., Kong L., Su J., Yin F., Ding A.H., Zanin-Zhorov A., Dustin M.L., Tao J., Craft J., Yin Z., Feng J.Q., Abramson S.B., Yu X.P., Liu C.J. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science 2011, 332:478-484.
6. Shen C., Maerten P., Geboes K., Van Assche G., Rutgeerts P., Ceuppens J.L. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin. Immunol. 2005, 115:250-259.
7. Wong M., Ziring D., Korin Y., Desai S., Kim S., Lin J., Gjertson D., Braun J., Reed E., Singh R.R. TNFa blockade in human diseases: mechanisms and future directions. Clin. Immunol. 2008, 126:121-136.
8. Karampetsou M.P., Andonopoulos A.P., Liossis S.N. Treatment with TNFα blockers induces phenotypical and functional aberrations in peripheral B cells. Clin. Immunol. 2011, 140:8-17.
9. Bosè F., Raeli L., Garutti C., Frigerio E., Cozzi A., Crimi M., Caprioli F., Scavelli R., Altomare G., Geginat J., Abrignani S., Reali E. Dual role of anti-TNF therapy: enhancement of TCR-mediatedT cell activation in peripheral blood and inhibition of inflammation in target tissues. Clin. Immunol. 2011, 139:164-176.
10. Karampetsou M.P., Liossis S.N., Sfikakis P.P. TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM 2010, 103:917-928.
11. Lin J., Ziring D., Desai S., Kim S., Wong M., Korin Y., Braun J., Reed E., Gjertson D. Singh RRTNFalpha blockade in human diseases: an overview of efficacy and safety. Clin. Immunol. 2008, 126:13-30.
12. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., Beenhouwer D.O. Granulomatus infectious diseases associated with TNF antagonists. Clin. Infect. Dis. 2004, 38:1261-1265. correction Clin Infect Dis 2004;39:1254-5.
13. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., Gromnica-Ihle E., Antoni C., Herzer P., Kekow J., Schneider M., Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005, 52:3403-3412.
14. Moustou A.E., Matekovits A., Dessinioti C., Antoniou C., Sfikakis P.P., Stratigos A.J. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J. Am. Acad. Dermatol. 2009, 61:486-504.
15. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun. Rev. 2010, 10:46-50.
16. Elezoglou A., Kafasi N., Kaklamanis P.H., Theodossiadis P.G., Kapsimali V., Choremi E., Vaiopoulos G., Sfikakis P.P. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin. Exp. Rheumatol. 2007, 25(4 Suppl 45):S65-S69.
17. Yin F., Banerjee R., Thomas B., Zhou P., Qian L., Jia T., Ma X., Ma Y., Iadecola C., Beal M.F., Nathan C., Ding A. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J. Exp. Med. 2010, 207:117-128.
18. Kessenbrock K., Fröhlich L., Sixt M., Lämmermann T., Pfister H., Bateman A., Belaaouaj A., Ring J., Ollert M., Fässler R., Jenne D.E. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin. J. Clin. Invest. 2008, 118:2438-2447.
19. Bateman A., Bennett H.P. The granulin gene family: from cancer to dementia. Bioessays 2009, 31:1245-1254.
20. Kao A.W., Eisenhut R.J., Martens L.H., Nakamura A., Huang A., Bagley J.A., Zhou P., de Luis A., Neukomm L.J., Cabello J., Farese R.V., Kenyon C. A neurodegenerative disease mutation that accelerates the clearance of apoptotic cells. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4441-4446.
21. Tada Y., Ho A., Koarada S., Morito F., Ushiyama O., Suzuki N., Kikuchi Y., Ohta A., Mak T.W., Nagasawa K. Collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor-1. Clin. Immunol. 2001, 99:325-333.
22. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000, 288(5475):2351-2354.
23. Deng G.M., Liu L., Tsokos G.C. Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice. Arthritis Rheum. 2010, 62:2424-2431.
24. Cao J., Meng F., Gao X., Dong H., Yao W. Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination. Protein J. 2011, 4:281-289.
25. Wang Y.L., Chou F.C., Chen S.J., Lin S.H., Chang D.M., Sytwu H.K. Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases - an unrevealed role in downregulation of Th17 cells. J. Autoimmun. Jun 30 2011, [Epub ahead of print].
26. Tak P.P., Kalden J.R. Advances in rheumatology: new targeted therapeutics. Arthritis Res. Ther. 2011, 13(Suppl 1):S5.
27. Weinblatt M.E., Kavanaugh A., Genovese M.C., Musser T.K., Grossbard E.B., Magilavy D.B. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 2010, 363:1303-1312.